A Phase I/II Study of the mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Patients With Previously Treated Glioblastoma Multiforme
The standard or usual treatment for this disease is standard chemotherapy alone. For the
first part of this study (phase I), there are two purposes. The first is to see whether
AZD2014 can affect glioblastoma multiforme, and the second purpose is to see what effects it
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society